Highest-materiality recent filing
Inogen Q1 revenue up 3.4% to $85.1M; net loss widens to $8.3M
GAAP net loss of $8.3M vs $6.2M loss in Q1 2025; adjusted net loss $4.0M vs $2.9M.
Inogen appoints Vafa Jamali to board, enters cooperation agreement with Kent Lake
Vafa Jamali appointed as independent Class I director effective June 15, 2026 or 2026 annual meeting.
Inogen names Jason Richardson CFO, appoints CMO and VP Sales; reaffirms 2026 guidance
Jason Richardson appointed CFO effective April 6, 2026; previously CFO of Baxter's Health System & Technologies segment.
Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.
Inogen prelim Q4 rev ~$82M (+2% YoY); FY25 rev ~$349M (+4%); order delays into H1 2026
Q4 2025 preliminary revenue ~$82M, up ~2% YoY; full-year 2025 ~$349M, up ~4% YoY.
Inogen Q3 revenue $92.4M (+4% YoY); adj. EBITDA positive $2.3M; raises FY guidance
Revenue $92.4M, up 4% YoY; seventh consecutive quarter of mid-single-digit growth.
Inogen Q2 2025 revenue $92.3M (+4% YoY); raises full-year revenue guidance
Revenue $92.3M, up 4% YoY; sixth consecutive quarter of mid-single-digit growth.
Inogen Q1 2025 revenue $82.3M (+5.5% YoY); adjusted EBITDA turns positive
Total revenue $82.3M, up 5.5% YoY (7.1% constant currency) on higher B2B demand.
Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly
Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.
Inogen partners with Yuwell; receives ~$27.2M investment for 9.9% stake at $10.36/share
Strategic collaboration with Jiangsu Yuyue to distribute respiratory products in US/Europe and expand into China.
Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance
Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.
Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment
FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.
Inogen Q3 revenue up 5.8% to $88.8M; adjusted EBITDA turns positive $0.5M
Revenue $88.8M (+5.8% YoY) driven by business-to-business gains; direct-to-consumer and rental revenue fell.
Inogen Q2 revenue up 6.1% to $88.8M; net loss narrows to $5.6M
Total revenue $88.8M (+6.1% YoY) driven by international and domestic B2B sales.
Inogen stockholders approve amended 2023 equity plan, elect directors at annual meeting
Stockholders approved Amended & Restated 2023 Equity Incentive Plan: 14,014,481 for, 2,868,882 against, 79,455 abstentions (2,335,280 broker non-votes).
Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024
Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.
Inogen Q4 revenue $75.9M (-14% YoY); FY net loss $102.4M, adj EBITDA -$37.8M
Q4 revenue $75.9M vs $88.1M YoY; full-year revenue $315.7M vs $377.2M in 2022.
Inogen appoints Michael Bourque as CFO effective March 4, 2024
Michael Bourque appointed EVP, CFO and Treasurer; succeeds interim CFO Mike Sergesketter who stays for transition.
On January 31, 2025, the Board, upon recommendation of the Nominating and Governance Committee, appointed Mira Kirti Sahney to the Board, effective January 31, 2025.
On January 30, 2025, Thomas A. West notified Inogen, Inc. (“the Company”) of his resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of January 30, 2025.
the Company and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.
On May 6, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Kevin P. Smith to serve as Executive Vice President, Business Development, General Counsel and Secretary of the Company, effective July 22, 2024.
On July 2, 2024, Inogen, Inc. (the “Company”) and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.
Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024
On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.
On January 21, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Michael Bourque to serve as Executive Vice President, Chief Financial Officer and Treasurer (“CFO”) of the Company, effective March 4, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings